{"id":"besifovir-dipivoxil","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated creatinine / renal impairment"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL922","moleculeType":"Small molecule","molecularWeight":"501.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Besifovir is a prodrug that is converted to besifovir in vivo, where it acts as a nucleotide analog inhibitor of hepatitis B virus (HBV) reverse transcriptase. By incorporating into the growing viral DNA chain, it causes chain termination and prevents viral replication. It has demonstrated activity against both wild-type HBV and lamivudine-resistant strains.","oneSentence":"Besifovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:20:42.811Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT04249908","phase":"PHASE1","title":"Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2020-02-13","conditions":"Renal Impairment","enrollment":40},{"nctId":"NCT04202536","phase":"PHASE4","title":"Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2019-05-29","conditions":"Hepatitis B, Besifovir Dipivoxil Maleate, Tenofovir Disoproxil Fumarate","enrollment":152},{"nctId":"NCT03885778","phase":"PHASE4","title":"A Food Effect Study of Besifovir in Healthy Subjects","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2019-01-13","conditions":"Food Effect, Health Subjects","enrollment":15},{"nctId":"NCT03604016","phase":"PHASE4","title":"Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2018-09-23","conditions":"Hepatitis B","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Besivo tab"],"phase":"marketed","status":"active","brandName":"Besifovir dipivoxil","genericName":"Besifovir dipivoxil","companyName":"IlDong Pharmaceutical Co Ltd","companyId":"ildong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Besifovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}